Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase II trial compares the effect of folate receptor alpha dendritic cells (FRαDCs) to placebo in treating patients with stage III or IV ovarian, fallopian tube or primary peritoneal cancer. FRαDCs, a dendritic cell vaccine, is made from a person's white blood cells. The white blood cells are treated in the laboratory to make dendritic cells (a type of immune cell) mixed with folate receptor alpha (FRalpha), a protein found in high levels on ovarian tumor cells. FRαDCs work by boosting the immune system to recognize and destroy the tumor cells by targeting the FRalpha protein on the tumor cell. Placebo is an inactive substance that looks the same as, and is given the same way as, the active drug or treatment being tested. The effects of the active drug are compared to the effects of the placebo. Giving FRαDCs may work better in preventing or delaying recurrence compared to placebo in patients with stage III or IV ovarian, fallopian tube, or primary peritoneal cancer.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 18 lat lub więcej.
- •Potwierdzony rak jajnika, jajowodu lub otrzewnej (epithelialny) w stadium III lub IV.
- •Ukończenie operacji usunięcia guza i jednego cyklu chemioterapii opartej na platynie (od 4 do 12 tygodni przed rozpoczęciem badania).
- •Wyniki badań genetycznych (zarówno dziedzicznych, jak i somatycznych) zostały ukończone.
- •Stan ogólny pacjentki pozwala na aktywność (ECOG 0, 1 lub 2).
- •Przewidywany czas przeżycia wynosi co najmniej 6 miesięcy.
- •Poziom hemoglobiny we krwi jest odpowiedni (nie starszy niż 15 dni przed rozpoczęciem badania).
- •Liczba białych krwinek (neutrofile) jest odpowiednia (nie starsza niż 15 dni przed rozpoczęciem badania).
✗ Disqualifies
- •Stwierdzenie szkodliwych mutacji w genach BRCA1/BRCA2.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- October 2, 2026
- Sex
- Female only
Therapies / drugs in trial
Locations (3)
Mayo Clinic in Arizona
Scottsdale, United States
Mayo Clinic in Florida
Jacksonville, United States
Mayo Clinic in Rochester
Rochester, United States
Trial contact
Clinical Trials Referral Office
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 10/3/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.